Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

NCT07238569 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

516

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)
Nasopharangeal Cancer

Interventions

DRUG: Adebrelimab (PD-L1 inhibitor)
DRUG: Cisplatin (100mg/m2)
RADIATION: Intensity-modulated radiotherapy
DRUG: Capecitabine

Sponsor

Sun Yat-sen University